What Helogen does

Helogen Corporation is a space biology and infrastructure company building fully automated, AI-driven orbital laboratories in low Earth orbit for biomanufacturing and biomedical research. The company develops and operates an integrated platform of space-qualified instruments, including the HEL-IOS orbital biomedical operating system, autonomous cultivation platforms (CELS and HEL-ICS), and specialized hardware such as the Multi-Modal Culture Sequencer (MCS), Multi-Modal Culture Analyzer (MCA), Gene Sequencer, and Bioreactor. Its product architecture is designed to enable persistent, high-throughput biological research and the production of high-value biomaterials that the company contends cannot be made under Earth's gravity, with applications spanning drug discovery, oncology screening, organoid development, and advanced biopolymer manufacturing.

The company generates revenue through mission-based service engagements with pharmaceutical and biotech firms, research institutions, and government agencies. Its commercial pipeline includes three orbital life sciences missions: HC-252-Conan (launched November 2025, focused on radiation mitigation and oncology drug development), HC-263-Cyrus (scheduled March 2026, focused on high-throughput screening), and HC-264-TBD (scheduled June 2026). Helogen distributes its capabilities through dedicated enterprise sales channels, research institution collaborations (e.g., MAHE, Memorial Sloan Kettering, AgResearch New Zealand), and embedding partnerships with commercial space station operators such as Starlab Space.

Helogen is a privately held company headquartered in New York with operations support in Houston, employing 11–50 people. Its strategic positioning rests on a combination of proprietary orbital automation technology, deep institutional partnerships (including with NASA and India's Centre of Excellence for Space Technology), and embedded platform integration with commercial LEO infrastructure. The company's go-to-market is partnership- and mission-driven, and its growth signals include a cadence of orbital missions, geographic expansion into India, and the 2025 acquisition of Vellon Space.

Name

Helogen

Legal name

Helogen Corporation

Website

https://helogen.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Helogen Corporation builds fully automated, AI-driven orbital laboratories in low Earth orbit that produce high-value biomaterials and enable drug discovery research for pharmaceutical companies, research institutions, and government agencies.

Ownership category

akta.pro rank

Product category

Space Biomanufacturing

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), AI Hardware IP & Chiplet/Packaging for Accelerators (EDA/IP, advanced packaging) (HDAAAAAL)

Keywords

• Orbital biomanufacturing
• Space biology research
• Microgravity drug discovery
• Biomedical operating systems
• Autonomous orbital labs

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Orbital Manufacturing Services: Service-based revenue from providing orbital manufacturing capabilities to pharmaceutical and biotech companies. Customers access microgravity conditions for drug development, biomaterial production, and research that cannot be conducted on Earth.
2. Space Mission Partnerships: Revenue generated through dedicated space missions (HC-252-Conan, HC-263-Cyrus, HC-264-TBD) where partners fund specific research objectives including drug development, oncology screening, and material manufacturing in orbit.
3. Research Collaborations: Partnership-based revenue from collaborative research agreements with institutions like MAHE for space-based biomedical research including organoid development and advanced biomaterial studies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Helogen builds and operates fully automated, AI-driven orbital factories in low Earth orbit that produce high-value biomaterials and conduct drug development under microgravity conditions. Its core stack comprises HEL-IOS (the world's first orbital biomedical operating system), the CELS and HEL-ICS autonomous orbital automation platforms, and dedicated instruments (MCS, MCA, Gene Sequencer, Bioreactor) delivered through named missions such as HC-252-Conan, HC-263-Cyrus, and HC-264-TBD for pharmaceutical, biotech, government, and academic customers.

Product overview

Helogen is a space biology company offering an integrated platform of orbital bio-lab instruments and autonomous systems for manufacturing high-value biomaterials in microgravity. The core offering includes HEL-IOS (the world's first orbital biomedical operating system), autonomous orbital automation platforms (CELS and HEL-ICS), and specialized instruments (Multi-Modal Culture Sequencer, Multi-Modal Culture Analyzer, Gene Sequencer, and Bioreactor). These components work together to enable high-throughput screening, drug discovery, organoid development, and advanced biomedical research in low Earth orbit for applications in oncology, aging studies, and biopolymer manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• HEL-IOS: World's first orbital biomedical operating system enabling autonomous and scalable biological research and manufacturing in low Earth orbit.
• CELS
• HEL-ICS
• MCS (Multi-Modal Culture Sequencer)
• MCA (Multi-Modal Culture Analyzer)
• Gene Sequencer

Products and services

• HEL-IOS (Orbital Biomedical Operating System) World's first orbital biomedical operating system that enables autonomous and scalable biological research and manufacturing in low Earth orbit. Supports persistent, high-throughput discovery including protein crystallization, 3D cell growth models, and stem cell research, and is integrated into commercial space station ecosystems such as Starlab Space.
• Orbital Biomanufacturing Services

Quantifiable outcome

• 76 peer-reviewed microgravity studies published in 2025 (ISS)
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered major and core.

• CoE SpaceTech Foundation (Karnataka)majorStrategic or Co-development Partner · 1 May 2026Strategic MoU signed with India's first State-led Centre of Excellence for Space Technology in Bengaluru. Partnership aims to bridge R&D capability and market-ready solutions by supporting advanced research, industry-aligned training, startup incubation, and cross-sector applications of space technologies across agriculture, climate, disaster management, and national security.
• Manipal Academy of Higher Education (MAHE)coreStrategic or Co-development Partner · 10 April 2026Partnership agreement to pioneer space-based biomedical research focusing on advanced biomaterial development including organoids for muscle and bone loss studies. MAHE integrates its proprietary organoid research with Helogen's autonomous orbital automation platforms (CELS and HEL-ICS) to enable scalable experiments aligned with India's Bharatiya Antariksh Station initiatives.
• Starlab SpacecoreStrategic or Co-development Partner · 21 February 2026Partnership to integrate HEL-IOS, the world's first orbital biomedical operating system, into Starlab's commercial space station ecosystem. Enables autonomous and scalable biological research and manufacturing in low Earth orbit, supporting applications including protein crystallization for drug development, 3D cell growth models, and stem cell research.
• NASAcoreStrategic or Co-development PartnerCollaboration with NASA on real-time RNA sequencing using Helogen's Gene Sequencer, advancing autonomous genetics research to help humans live healthier lives in space.
• Memorial Sloan KetteringcoreStrategic or Co-development PartnerPartnership focused on groundbreaking oncology drug development. Conducting in-orbit high throughput screening to accelerate cancer prevention and treatment advancements.
• AgResearch New ZealandmajorStrategic or Co-development PartnerCollaboration advancing the in-space manufacturing of biocompatible polymers that will unlock novel applications in space and on planet Earth.
• Government InstitutionsmajorStrategic or Co-development PartnerPartnerships with leading government and global institutions offering decades of expertise and visionary innovation, essential for accelerating off-world manufacturing technologies that prioritize human well-being and planetary health.
• Research Organizations and UniversitiesmajorStrategic or Co-development PartnerInstitutional partners including global research organisations, universities, and biotech labs where generational leaps in science happen. Discoveries and innovations will generate progress shaping humanity's future.
• Commercial Space Station OperatorscoreStrategic or Co-development PartnerOrbital partners enabling large-scale, off-world manufacturing from commercial space stations to orbital infrastructure. Crucial collaborations for ushering in the post-gravity era where manufacturing moves beyond Earth.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Yuri Gravity: Germany-based biotech operating commercial microgravity research and biomanufacturing services. Directly comparable as a European-headquartered competitor targeting pharma R&D customers in LEO.
• BioServe Space Technologies: University of Colorado-based microgravity research lab with decades of ISS biological experiment heritage. Comparable as a long-standing provider of orbital life sciences platforms and instruments.
• Space Tango: Operates autonomous microgravity payloads and bio-manufacturing platforms on the ISS and commercial stations. Most direct comparator in orbital bio-lab services for pharma and biotech customers.

Regional players

• Made In Space (Redwire): Pioneered in-space manufacturing (3D printing, fiber optics). Comparable as a peer pursuing off-Earth manufacturing economics, though focused on materials rather than biology.

Broad incumbents

• Redwire Space: Larger space infrastructure provider with significant microgravity research heritage (via BioServe) and station hardware. Competes across the orbital bio payload and station ecosystem with a broader product portfolio.
• Starlab Space: Commercial space station joint venture (Voyager, Airbus, MDA, Hilton). Directly comparable as a station platform into which Helogen's HEL-IOS is integrated — both customer and potential competitor for onboard bio services.
• Axiom Space: Building commercial space station modules with research and biomanufacturing as core use cases. Comparable as an orbital infrastructure partner/customer that defines the addressable platform for Helogen's payloads.

Others

• Vellon Space: Space-manufacturing company acquired by Helogen in April 2025. Comparable as a now-subsidiary peer working on off-world manufacturing technologies in adjacent domains.
• Dassault Systèmes (BIOVIA): Named Helogen partner; provides life sciences digital simulation and lab informatics. Comparable as an ecosystem/adjacent player supporting in-silico-to-in-orbit biotech R&D workflows.

Emerging players

• LambdaVision: Uses microgravity to manufacture protein-based artificial retinas in LEO. Comparable as an emerging space biomanufacturer pursuing a single high-value therapeutic product.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helogen